BioSciKin competition for life sciences start-ups

BioSciKin competition for life sciences start-ups

Nanjing BioSciKin Co., Ltd (“BioSciKin” or “BSK” or the “Company”), an open investment and incubation platform in China for life science innovation has announced an international start-up competition for life sciences companies. Co-sponsors include influential Chinese industrial investors, pharmaceutical companies and influential Chinese media with the support of a powerful alliance of strategic investors. The contest will be held in 8 cities, in the US as well as in China. Winners in each preliminary will receive $30,000 in non-dilutive financing, with the top two companies from each region receiving a paid trip to Shanghai to present in front of Chinese investors.

Sponsors are:

● Simcere Pharmaceutical group

● BioSciKin

● Simcere State Key Laboratory of Translational Medicine and Innovative Drug R&D


● Firestone Inventing 


Who should apply?

The event welcomes both companies and entrepreneurial teams in life science, especially in precision medicine or e-health related areas include but are not limited to: Bio-bank, Biomarker, NGS, Gene Therapy, Molecular Diagnostics, Stem Cell, e-Health, IVD, 3D Printing, Big Data, POCT, Prenatal Diagnostics, Cell Therapy, Personalized Medicine, 4P Medicine etc.

How to participate

  • Application Deadline is March 15, 2016: please send an executive summary or no more than 10 slides in either PowerPoint or as a PDF along with your contact information to
  • SFO: 
  • About 10 startups will be selected to showcase their projects at preliminaries.  You will receive a formal invitation to the preliminaries.  Two teams with the highest ratings from the judging panel will advance to the final.
  • If you only want to attend as an audiance, please register using  the link below :
  • SFO:

    Rewards for winners:

    ●For each preliminary in the US: $30,000 for first prize (1 winner)  and the prize money is non-dilutive

    ●Trip to Shanghai to attend final competition in May 2016 for the top two finalists from each preliminary

    ●For final contestants: potential strategic investments from attending investors

    ●It is not manditory to set up Chiniese presence for the invested projects. 

    Option to leverage support from Simcere & BioSciKin: Collaboration opportunities in R&D, marketing, distribution etc.

    When & Where:

    East Coast Preliminary

    Date: April 05, 2016

    Time: 4:00-8:00 p.m. Eastern Time

    Location: 300 Technology Square, 8th Floor, MassBio Collaboration Room, Cambridge, MA 02139

    Co-organized by:

    Harvard Medical School Chinese Scholars and Scientists Association (HMS-CSSA),SAPA-NE,MIT-CHIEF,NECINA,CABA , 128 CUTE, ACMA

    Supporting organization: MassBio

    Publicity partner:  Massachusetts Life Sciences Center


    West Coast Preliminary

    Date: April 07, 2016

    Time: 6:00-10:00 p.m. Western Time

    Location: Stanford University, Room130, Li Ka Shing Learning and Knowledge Center, 291 Campus Drive, Stanford, CA 94305

    Co-organized by:

    Chinese American Biopharmaceutical Society (CABS)

    Association of Chinese Students and Scholars at Stanford (ACSSS)

    Supporting organization: CLSA




    Keynote Speaker:

    In Boston: Thomas C. Südhof, M.D.

    Nobel prized winner Dr. Thomas Christian Südhof is a German-American biochemist known for his study of synaptic transmission. Currently, he is a professor in the School of Medicine in the Department of Molecular and Cellular Physiology, and by courtesy in Neurology, and in Psychiatry and Behavioral Sciences at Stanford University. Südhof, James Rothman and Randy Schekman are the 2013 Nobel Prize in Physiology or Medicine laureates for their work on vesicle trafficking. 

    In SFO: Dr. Lin Wu

    Dr Lin Wu is Vice President, Development for the Sequencing Business Unit of Roche Diagnostics. Dr. Wu has strong background in IVD assay development and registration. She led the development of the first microarray-based pharmacogenetic assay approved by the FDA, AmpliChip CYP450, and assumed various leadership roles during the development of the cobas oncology portfolio. Dr. Wu pioneered the scientific research work in detecting tumor DNA in blood, which eventually led the launch of cobas EGFR blood assay. This work was the first recipient of Roche Diagnostic DIAmond Award for R&D Innovation.Dr. Lin Wu received her Ph. D. in Molecular Biology from State University of New York at Buffalo. Prior joining Roche, she completed her post-doctoral fellowship in cancer biology at Princeton University.

    Panel of Judges: 

    Pete Thomas

    Pete Thomas is a Managing Director of PointGuard Ventures(PGV). Prior to co-founding PointGuard Ventures, Pete co-founded ATA Ventures in 2004, a firm that raised $440M in capital across three funds during the last ten years. ATA has invested in over 40 early stage companies and Pete was on the board and directly involved in 11 of those companies and is presently on the board of Revera, Lavante, and Adesto Technologies and is an advisor to Theranos.

    Krish Panu

    Kris panu is a Managing Director of PointGuard Ventures(PGV). For more than two decades Krish has built successful technology businesses which have created multi-billion dollar markets. Prior to entering the venture capital industry, Krish has held executive positions in several influential companies including @Road, Inc., Atmel, Catalyst Semiconductor, Datapoint Corporation and Xicor etc.

    Roger Wyse

    Dr.  Roger Wyse is the Managing Partner of Spruce Capital Partners and BAR Capital Management. He chairs or serves on the boards of 11 private companies. He is Co-Chairman of the $162M Malaysian Life Sciences Capital Fund. He is also an internationally recognized scientist and was a Dean at 2 major research universities. He was founder and Chairman of the Alliance for Animal Genome Research. He is on Board of Industrial Section of BIO.

    Jason P. Hafler

    Senior Director of Investments and Principal of Sanofi-Genzyme BioVentures. Prior to SGBV, Jason served in many influential companies and organizations: RaNA Therapeutics, Atlas Venture, Flagship Ventures, JSB Partners, University of Cambridge etc. Jason serves on the Board of NeuroVia Inc. and Navitor Pharmaceuticals. In addition, he is on the Board of Trustees at the Buckingham Browne and Nichols school and on the Board of Directors of the Magdalene College Foundation.

    Luke Li

    Dr. Luke Li has 30 years of experience in biopharma and healthcare business. Currently, Dr. Li is a Managing Director at Ally Bridge Group (“ABG”), a global healthcare investment platform. Before joining ABG, Dr. Li has held Executive positions at Pfizer and Amgen. He was an Assistant Professor in Medicine at Washington University Medical School.

    Jason Wen

    Jason Wen is the Director of Technology Transfer at Boston College. He has a broad background combining experience in the life sciences, business, and patent law. Dr. Wen is a long time member of the Association of University Technology Managers (AUTM) and the Licensing Executives Society (LES). He is also a Registered Technology Transfer Professional (RTTP) and a United States Patent and Trademark Office Registered Patent Agent.

    Michael Draper

    Sanofi North America’s Head of External Science and Partnering on East Coast.

    Other judges include delegates from BioSciKin

    BioSciKin is actively seeking investment opportunities in precision medicine filed and has made more than 10 investments over past two years in US, Korea and China, with typically investment size ranging from 0.5 million to 10 million USD. 

    For more information, please email to BSK’s US contacts and ask for a full description of this event.

    East Coast: or call 617-319-8265 or West Coast: or call 626-272-6619.


    About Simcere

    Simcere is an emerging leader in developing, manufacturing and marketing of innovative medicines and branded generics in China. Simcere was the first Chinese chemical and biological drug company to list on the NYSE in 2007. In 2013, the company went private for strategic considerations. In 2015, Simcere’s translational medicine and innovative drug R&D platform has been recognized as a State Key Laboratory by the National Ministry of Science and Technology. The company has been actively pursuing cross-border partnerships to bringing global innovation to China. In Boston and New Jersey, Simcere has two offices in the US for accelerating international business development.


    About BioSciKin

    BioSciKin (BSK) is an open platform in China for life science entrepreneurs and innovators. Focuses on three major healthcare areas: novel therapeutics, medical devices and mobile healthcare services, BSK is looking for partnership from all over the world for co-development of innovative approaches in precision medicine. In Nanjing, Shanghai and Tianjin, BSK has established 3 R&D-oriented incubation parks with advanced R&D facilities to provide entrepreneurs with customized service and support packages. For more information, please go to BSK’s official website:

    You can also email to Ms. Ray Zhang, Senior BD director, BioSciKin ( )



    HEALTHCARE EXECUTIVE is an influential magazine in the Chinese healthcare industry. The 30,000-per-month publications have reached up to the departments supervising the pharmaceutical industry, such as CFDA, and down to the pharmas, investment and consulting institutions and industrial parks.


    About Firestone

    Firestone focuses on innovation and entrepreneurship services in healthcare industry. By connecting Internet and healthcare innovation and entrepreneurship, Firestone will use its abundant resources to create entrepreneurial ecology, help entrepreneurs growing rapidly in correct directions and accelerate the commercialization process of entrepreneurship projects.


    Announcement of New Office Location

    Simcere is delighted to announce our recent expansion into Boston. Our new Boston-area office is located on 245 First Street, Cambridge MA 02142. This new expansion enables Simcere to provide additional functions to all our clients, and to be a part of one of the world’s leading ecocystems for life sciences innovation in the Greater Boston region. These additional capabilities will help Simcere in providing exceptional services to our industry partners. Simcere worked closely with the Massachusetts Life Sciences Center and MassBio as part of the company’s U.S. location search. For additional information, please contact Dr. Sean Cao at (617) 444 –8778.


    “The Boston/Cambridge area has evolved from a cluster of world-class research centers to the most active global innovation hub for the biotech and pharmaceutical industries,” Dr. Cao told MassBio in an interview.“Establishing a branch in Cambridge allows us to work very closely with up-and-coming biotechs, large pharmas and top-notch research institutions."


    “We are thrilled to welcome Simcere to the Massachusetts life sciences cluster,” said Robert K. Coughlin, President & CEO of MassBio. “We know that they will contribute to and benefit from our community and are pleased to see that they are already connecting with local entrepreneurs for the upcoming BioSciKin startup competition.”


    “We are excited to welcome Simcere, a leading pharmaceutical company in China, to their new office in Cambridge,” said Travis McCready, President & CEO of the Massachusetts Life Sciences Center. “They are joining a growing concentration of Chinese life sciences companies that are choosing Massachusetts as a great place to locate their U.S. operations. We look forward to promoting the business plan competition that Simcere and BioSciKin are sponsoring here, that will allow promising start-ups in Massachusetts to access investors in China.”

    Simcere’s Boston office contact information:

    Phone: (617) 444 – 8778



    Copyright © 2014
    All Rights Reserved